On April 28, 2022, Bristol Myers Squibb announced the FDA approval of the specified NDA, a move that is expected to bolster its commercial portfolio and broaden its market presence in this therapeutic class. This regulatory milestone serves as a strategic asset that enhances the company's pipeline value and capability to address unmet clinical needs.